AN2 Therapeutics, Inc 10-Q for FY2026 Q3
AN2 Therapeutics, Inc. (ANTX)
10-Q
2026-11-09
For: 2026-09-30
View Original
Added on
November 09, 2026
About this 10-Q
AN2 Therapeutics, Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
AN2 Therapeutics had $80.2 million in cash and investments, expecting its current operating plan to fund operations for at least 12 months. Phase 2 startup was underway for epetraborole in polycythemia vera, while an investigator-initiated M. abscessus trial enrolled patients. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $7.96M
- compared with a net loss of $9.35M a year earlier
- Diluted EPS
- -$0.17
- compared with -$0.31 a year earlier